A cura di Alessandra Russo. Specialista in Tossicologia Medica. Messina
|
Principio attivo |
Effetto |
|
Donepezil (1,2) |
Possibile aumento del rischio di prolungamento dell’intervallo QT |
|
Idrossiclorochina (3-5) |
Possibile aumento del rischio di prolungamento dell’intervallo QT |
|
Lofexidina (6) |
Possibile aumento del rischio di prolungamento dell’intervallo QT e di torsione di punta |
Bibliografia
- Takaya T, et al.Torsades de Pointes with QT prolongation related to donepezil use. J Cardiol2009; 54:507-511.
- Tanaka A. Donepezil-induced adverse side effects of cardiac rhythm: 2 cases report of atrioventricular block and Torsade de Pointes. InternMed 2009; 48:1219-1223.
- Chen CY. Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia. ClinToxicol (Phila) 2006; 44:173-175.
- Morgan ND. Suspected hydroxychloroquine-associated QT-interval prolongation in a patient with systemic lupus erythematosus. J ClinRheumatol 2013; 19:286-288.
- Product Information: PLAQUENIL(R) oral tablets, hydroxychloroquine sulfate oral tablets. Concordia PharmaceuticalsInc (per FDA), Kansas City, MO, Jan, 2017.
- Product Information: LUCEMYRA(TM) oral tablets, lofexidine oral tablets. US WorldMeds LLC (per FDA), Louisville, KY, May, 2018.
Link